Loading
IARC estimates 8,902 new cancer cases and 5,139 cancer deaths in Kyrgyzstan in 2024; the commonest new cancers are breast, stomach and trachea, bronchus and lung. This page is assembled automatically from OnCo's data, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 1,218 | 33.9 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Stomach | 1,076 | 16.7 | Gastric & gastro-oesophageal junction cancer |
| Trachea, bronchus and lung | 816 | 12.9 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 706 | 11.3 | Colorectal cancer |
| Cervix uteri | 538 | 14.9 | Cervical cancer |
| Liver and intrahepatic bile ducts | 434 | 6.9 | Hepatocellular carcinoma |
| Prostate | 341 | 14.7 | Prostate cancer |
| Corpus uteri | 266 | 7.4 | Endometrial cancer |
| Leukaemia | 258 | 3.7 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Pancreas | 256 | 4.1 | Pancreatic ductal adenocarcinoma |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Stomach | 876 | 13.8 | Gastric & gastro-oesophageal junction cancer |
| Trachea, bronchus and lung | 684 | 10.8 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Liver and intrahepatic bile ducts | 409 | 6.6 | Hepatocellular carcinoma |
| Breast | 342 | 9.6 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Colorectum | 331 | 5.3 | Colorectal cancer |
| Cervix uteri | 291 | 8.1 | Cervical cancer |
| Pancreas | 250 | 4.0 | Pancreatic ductal adenocarcinoma |
| Brain, central nervous system | 201 | 2.9 | Glioma & glioblastoma |
| Oesophagus | 188 | 3.1 | Oesophageal cancer |
| Ovary | 170 | 4.8 | Ovarian cancer |
No trial record in OnCo lists a site in Kyrgyzstan. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Kyrgyzstan.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Kyrgyzstan is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Kyrgyzstan is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.